Edit Várkondi, PhD, Head of Diagnostic Strategy and Services, and Júlia Déri, Precision Oncology Expert and Head of the Virtual Molecular Tumor Board, will represent Oncompass Medicine, a Genomate Health company, at ESMO Congress 2026 in Madrid.

‍

As cancer research advances, one question remains central to our work: how can we translate a deeper understanding of tumor biology into meaningful treatment options for individual patients?

At Oncompass Medicine, this means supporting patients and physicians through complex cancer decisions, connecting molecular diagnostics, expert interpretation, and multidisciplinary discussion. Genomate Health’s computational reasoning technology supports this work by helping interpret molecular evidence in the context of an individual tumor. The same understanding also informs drug development: identifying patient populations that may benefit from a therapy, exploring additional indications, and investigating treatment opportunities that may otherwise be overlooked.

At ESMO, Edit and Júlia look forward to exchanging experience with clinicians and researchers, following the latest scientific developments, and exploring partnerships across molecular diagnostics and precision oncology.

‍

Attending ESMO Congress 2026? Get in touch  to arrange a meeting with Edit and Julia ↗